Top News from ESC Congress 2018

All The Most Important News and Updates form the European Society of Cardiology Congress – ESC 2018

AstraZeneca is advancing understanding of cardio-renal-metabolic interconnectivity with new evidence at ESC 2018

August 25, 2018

AstraZeneca and MedImmune, its global biologics research and development arm, presented new data from its Cardiovascular, Renal and Metabolism (CVRM) portfolio of medicines at the ESC Congress, aiming to help inform clinical practice for the treatment of patients with overlapping CVRM diseases and multiple risk factors. Highlights included new real-world evidence on patients most at risk of future cardiovascular events, including death, underlining the need for improved secondary prevention including dual antiplatelet therapy (DAPT). The latest research also aims to inform clinical practice in patients with type-2 diabetes treated with glucose-lowering drugs who may also have coronary artery disease and/or experienced a prior heart attack or stroke

Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode

August 25, 2018

Data from the TRANSITION study presented at the ESC Congress in Munich, Germany has shown that Entresto® (sacubitril/valsartan) can be initiated early and safely in a wide range of heart failure patients with reduced ejection fraction (HFrEF) who have been stabilized after hospitalization due to an acute heart failure episode. Patients involved in the study included those with no prior experience of Entresto or conventional HF therapies, as well as those with prior experience of conventional HF therapies.

Too much of a good thing? Very high levels of “good” cholesterol may be harmful

August 25, 2018

Very high levels of high-density lipoprotein (HDL or “good”) cholesterol may be associated with an increased risk of heart attack and death, according to research presented at ESC Congress 2018. Participants with HDL cholesterol levels greater than 60 mg/dl (1.5 mmol/L) had a nearly 50% increased risk of dying from a cardiovascular cause or having a heart attack compared to those with HDL cholesterol levels 41–60 mg/dl (1.1–1.5 mmol/L).

Short and fragmented sleep linked to hardened arteries

August 26, 2018

Sleeping less than six hours or waking up several times in the night is associated with an increased risk of asymptomatic atherosclerosis, which silently hardens and narrows the arteries, according to results of the PESA study presented at ESC Congress 2018.

Janssen Announces Results from MARINER and COMMANDER HF Studies

August 27, 2018

Janssen has announced the results of the Phase 3 MARINER and COMMANDER HF (heart failure) studies, which were presented this week at the European Society of Cardiology (ESC) Congress 2018 and simultaneously published in The New England Journal of Medicine. In both studies, there was no significant difference found between XARELTO® (rivaroxaban) and placebo for the primary efficacy endpoints. XARELTO® did, however, demonstrate a consistent safety profile.

Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at The ESC Congress 2018

August 27, 2018

Pfizer Inc. has announced the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo over a 30-month period (P=0.0006) in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is a rare, fatal, and underdiagnosed condition associated with progressive heart failure for which there are no approved pharmacologic treatments.

Long-Term Cardiovascular Outcomes Data for Anti-Obesity Agent Belviq® Presented at The European Society of Cardiology and Published in The New England Journal of Medicine

August 28, 2018

Eisai Co., Ltd. has announced that results from the Cardiovascular Outcomes Trial (CAMELLIA-TIMI 61) in patients treated with lorcaserin hydrochloride (generic name, product name in the U.S.: BELVIQ®) were highlighted in an oral presentation at the European Society of Cardiology (ESC) Congress 2018 held in Munich, Germany, and concurrently published in the New England Journal of Medicine, one of the world’s most influential medical journals. BELVIQ is the first ever weight loss medication approved for chronic weight management which has been proven to not increase the incidence of major cardiovascular (CV) events in a dedicated long-term cardiovascular outcome trial.

Top News from ESC Congress 2018 last edit: 2018-09-03T20:42:47+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar